These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 35922717)

  • 1. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of biparametric and multiparametric MRI in the diagnosis of prostate cancer.
    Xu L; Zhang G; Shi B; Liu Y; Zou T; Yan W; Xiao Y; Xue H; Feng F; Lei J; Jin Z; Sun H
    Cancer Imaging; 2019 Dec; 19(1):90. PubMed ID: 31864408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI.
    Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY
    Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Values of multiparametric and biparametric MRI in diagnosing clinically significant prostate cancer: a multivariate analysis.
    Feng X; Chen X; Peng P; Zhou H; Hong Y; Zhu C; Lu L; Xie S; Zhang S; Long L
    BMC Urol; 2024 Feb; 24(1):40. PubMed ID: 38365673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI.
    Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH
    AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI).
    Gatti M; Faletti R; Calleris G; Giglio J; Berzovini C; Gentile F; Marra G; Misischi F; Molinaro L; Bergamasco L; Gontero P; Papotti M; Fonio P
    Abdom Radiol (NY); 2019 May; 44(5):1883-1893. PubMed ID: 30788558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Positive Predictive Values of Biparametric MRI and Multiparametric MRI-directed Transrectal US-guided Targeted Prostate Biopsy.
    Schieda N; Nisha Y; Hadziomerovic AR; Prabhakar S; Flood TA; Breau RH; McGrath TA; Ramsay T; Morash C
    Radiology; 2024 Jun; 311(3):e231383. PubMed ID: 38860899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthetic magnetic resonance imaging for primary prostate cancer evaluation: Diagnostic potential of a non-contrast-enhanced bi-parametric approach enhanced with relaxometry measurements.
    Arita Y; Akita H; Fujiwara H; Hashimoto M; Shigeta K; Kwee TC; Yoshida S; Kosaka T; Okuda S; Oya M; Jinzaki M
    Eur J Radiol Open; 2022; 9():100403. PubMed ID: 35242886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy of biparametric versus multiparametric prostate MRI: assessment of contrast benefit in clinical practice.
    Zawaideh JP; Sala E; Shaida N; Koo B; Warren AY; Carmisciano L; Saeb-Parsy K; Gnanapragasam VJ; Kastner C; Barrett T
    Eur Radiol; 2020 Jul; 30(7):4039-4049. PubMed ID: 32166495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study.
    Choi MH; Kim CK; Lee YJ; Jung SE
    AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of dynamic contrast-enhanced (DCE) imaging for prostate cancer detection depending on readers experience in prostate MRI.
    Ziayee F; Schimmöller L; Boschheidgen M; Kasprowski L; Al-Monajjed R; Quentin M; Radtke JP; Albers P; Antoch G; Ullrich T
    Clin Radiol; 2024 Mar; 79(3):e468-e474. PubMed ID: 38185579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low cancer yield in PI-RADS 3 upgraded to 4 by dynamic contrast-enhanced MRI: is it time to reconsider scoring categorization?
    Messina E; Pecoraro M; Laschena L; Bicchetti M; Proietti F; Ciardi A; Leonardo C; Sciarra A; Girometti R; Catalano C; Panebianco V
    Eur Radiol; 2023 Aug; 33(8):5828-5839. PubMed ID: 37045981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING).
    Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA
    Eur Urol Focus; 2024 Mar; 10(2):332-338. PubMed ID: 38402105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnostic performance in clinically significant prostate cancer with PI-RADS version 2.1: simplified bpMRI versus standard mpMRI.
    Song J; Zhao C; Zhang F; Yuan Y; Wang LM; Sah V; Zhang J; Weng W; Yang Z; Wang Z; Wang L
    Abdom Radiol (NY); 2023 Feb; 48(2):704-712. PubMed ID: 36464756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.